Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02304211 · ClinicalTrials.gov registry record · Early Phase 1
Intra-Arterial Microdosing: Proof-of-Concept in Humans
A Early Phase 1 study, sponsored by Duke University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 10
- Enrollment target
NCT02304211 is a Early Phase 1 study that has completed, run by Duke University. The registered enrollment target is 10 participants.
The verdict
NCT02304211, a Early Phase 1 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this protocol is to demonstrate that intra-arterial administration of a drug can generate information in a manner that faithfully mimics effects of systemic administration but with little or no systemic effects.
Interventions
- DRUG Insulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2014-12 |
| Est. Completion | 2015-07 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02304211
The ClinicalTrials.gov registry entry for NCT02304211 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Insulin is the first listed.
NCT02304211 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02304211 about?
NCT02304211 is a clinical study titled "Intra-Arterial Microdosing: Proof-of-Concept in Humans". The purpose of this protocol is to demonstrate that intra-arterial administration of a drug can generate information in a manner that faithfully mimics effects of systemic administration but with little or no systemic effects.
What is the current status of trial NCT02304211?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2014-12. Estimated completion is 2015-07.
What interventions are being tested in trial NCT02304211?
The interventions under investigation include: Insulin (DRUG).
Who is sponsoring clinical trial NCT02304211?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.